Oculus Innovative Sciences has entered into an agreement with OroScience granting Oroscience exclusive rights to market Microcyn-based oral products in the U.S., Canada, and Europe in exchange for ...
Nov 19 (Reuters) - Oculus Innovative Sciences Inc : * Reports revenues of $4.1 million for second quarter of fiscal 2014, meeting guidance of greater than $3.6 million * Q2 revenue $4.1 million * ...
Shares of Oculus Innovative Sciences (OCLS +3%) tick higher today after the company says it's been granted a CE Mark reclassification for its European formulation Dermacyn Wound Care. The newest ...
Oculus Innovative Sciences (OCLS) announces a public stock offering. It intends to use the net proceeds for the repayment of debt and to retire a portion of common stock previously issued to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback